JP2023526836A5 - - Google Patents

Info

Publication number
JP2023526836A5
JP2023526836A5 JP2022570454A JP2022570454A JP2023526836A5 JP 2023526836 A5 JP2023526836 A5 JP 2023526836A5 JP 2022570454 A JP2022570454 A JP 2022570454A JP 2022570454 A JP2022570454 A JP 2022570454A JP 2023526836 A5 JP2023526836 A5 JP 2023526836A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
cov
sars
mek inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022570454A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023526836A (ja
Filing date
Publication date
Priority claimed from EP20175739.0A external-priority patent/EP3912623B1/en
Application filed filed Critical
Publication of JP2023526836A publication Critical patent/JP2023526836A/ja
Publication of JP2023526836A5 publication Critical patent/JP2023526836A5/ja
Pending legal-status Critical Current

Links

JP2022570454A 2020-05-20 2021-05-20 コロナウイルス感染症および/またはcovid-19サイトカインストームの処置または予防のためのmek阻害剤 Pending JP2023526836A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20175739.0A EP3912623B1 (en) 2020-05-20 2020-05-20 Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm
EP20175739.0 2020-05-20
PCT/EP2021/063485 WO2021234097A1 (en) 2020-05-20 2021-05-20 Mek-inhibitors for the treatment or prevention of coronavirus infections and/or covid-19 cytokine storm

Publications (2)

Publication Number Publication Date
JP2023526836A JP2023526836A (ja) 2023-06-23
JP2023526836A5 true JP2023526836A5 (cg-RX-API-DMAC7.html) 2024-05-30

Family

ID=70802645

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022570454A Pending JP2023526836A (ja) 2020-05-20 2021-05-20 コロナウイルス感染症および/またはcovid-19サイトカインストームの処置または予防のためのmek阻害剤

Country Status (11)

Country Link
US (1) US20230241014A1 (cg-RX-API-DMAC7.html)
EP (2) EP3912623B1 (cg-RX-API-DMAC7.html)
JP (1) JP2023526836A (cg-RX-API-DMAC7.html)
KR (1) KR20230013077A (cg-RX-API-DMAC7.html)
CN (1) CN116635022A (cg-RX-API-DMAC7.html)
AU (1) AU2021277517A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022023013A2 (cg-RX-API-DMAC7.html)
CA (1) CA3178137A1 (cg-RX-API-DMAC7.html)
ES (1) ES2995196T3 (cg-RX-API-DMAC7.html)
MX (1) MX2022014561A (cg-RX-API-DMAC7.html)
WO (1) WO2021234097A1 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3697405T1 (sl) 2017-10-17 2021-11-30 Atriva Therapeutics Gmbh Novi zaviralec MEK za zdravljenje virusnih in bakterijskih okužb
LU101183B1 (en) * 2019-04-16 2020-10-16 Atriva Therapeutics Gmbh Novel mek-inhibitor for the treatment of viral and bacterial infections
CN115151533B (zh) 2020-01-10 2025-08-08 医疗免疫工程公司 Mek抑制剂及其治疗用途
WO2023084489A1 (en) * 2021-11-15 2023-05-19 Pfizer Inc. Methods of treating coronavirus disease 2019
EP4186500A1 (en) * 2021-11-24 2023-05-31 Atriva Therapeutics GmbH Mek inhibitors for the prevention and treatment of long covid syndrome
WO2024042050A1 (en) * 2022-08-22 2024-02-29 Atriva Therapeutics Gmbh Use of mek1/2 inhibitors to synergistically potentiate the antiviral effect of direct-acting anti-coronavirus drugs
WO2024073077A1 (en) * 2022-09-30 2024-04-04 60 Degrees Pharmaceuticals Llc Methods for the treatment and prevention of diseases or infections with mcp-1 involvement by administration of tafenoquine
CN116270588B (zh) * 2022-12-26 2025-07-25 中国科学技术大学 Mek1/2抑制剂u0126在治疗car t细胞引起的crs中的应用
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN117562890B (zh) * 2023-08-03 2026-05-19 中国医学科学院医药生物技术研究所 一种色酮类化合物在制备抗冠状病毒药物中的用途
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002249261A1 (en) * 2001-03-06 2002-09-19 Axxima Pharmaceuticals Ag Use of mek inhibitors for treating inflammation and virus induced hemorrhagic shock
SI3697405T1 (sl) * 2017-10-17 2021-11-30 Atriva Therapeutics Gmbh Novi zaviralec MEK za zdravljenje virusnih in bakterijskih okužb
LU101183B1 (en) * 2019-04-16 2020-10-16 Atriva Therapeutics Gmbh Novel mek-inhibitor for the treatment of viral and bacterial infections

Similar Documents

Publication Publication Date Title
CN114786659B (zh) 用于治疗汉坦病毒感染的mek抑制剂
Yousefi et al. A global treatments for coronaviruses including COVID‐19
JP5470047B2 (ja) 抗ウイルス組成物及び使用方法
CN113244212B (zh) 黄芩素在制备预防和/或治疗新型冠状病毒感染疾病的药物中的应用
KR102910416B1 (ko) 유행성 rna 바이러스 감염질환의 예방 또는 치료용 약제학적 조성물
EP4613275A1 (en) Pharmaceutical use of nucleoside compound
EP3934653B1 (en) Azelastine as antiviral treatment
JP2023518390A (ja) ウイルス感染症の治療若しくは予防又はウイルス感染症の発生を制限するための方法及び組成物
US4828830A (en) Method and composition for prophylaxis and treatment of viral infections
WO2017201030A1 (en) Methods of treating viral infection
RU2555765C2 (ru) Пироксикам для профилактического и терапевтического лечения герпетических инфекций
Steffenhagen et al. Evaluation of 6-azauridine and S-iododeoxyuridine in the treatment of experimental viral infections
WO2022079496A1 (en) A pharmaceutical composition of nitazoxanide, albendazole and pyrantel and method thereof
US20230030607A1 (en) Novel oxygen pulse therapy method for treating COVID19 and viral, bacterial, fungal or parasitic respiratory and other diseases
EP4132501A1 (en) New use of n,n-bis-2-mercaptoethyl isophthalamide
WO2022123323A1 (en) A pharmaceutical composition of artesunate and mefloquine and method thereof
US12171732B2 (en) Compositions and use of N-chlorotaurine for treatment and prevention of respiratory infections
CN114732815B (zh) 一种化合物在制备抗病毒药物中的用途及应用
RU2843665C1 (ru) Фармацевтическая композиция для профилактики или лечения эпидемического рнк-вирусного инфекционного заболевания
US20240115622A1 (en) Formulation for the prevention and/or treatment of covid-19
CN116036084A (zh) 千金藤素在制备治疗冠状病毒感染患者的药物中的用途
Yu et al. Timing-specific efficacy of antiviral baloxavir and anti-inflammatory oclacitinib monotherapies, and the benefits of their combination in treating influenza in mice
Sidwell et al. Primary immune system effects of the orally administered cyclopentane neuraminidase inhibitor RWJ-270201 in influenza virus-infected mice
CN121818590A (zh) Otx008在治疗hsv-1病毒感染中应用
HK40081976B (en) Pharmaceutical composition for preventing or treating epidemic rna viral infectious disease